MicroStockProfit.com releases investment report on Rexahn Pharmaceuticals

MicroStockProfit.com announces an investment report featuring Rexahn Pharmaceuticals Inc. (AMEX:RNN). The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

The full report is available at: www.microstockprofit.com/ads/RNN

Rexahn Pharmaceuticals Inc. (RNN) is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of treatments for cancer, central nervous system (CNS) disorders, sexual dysfunction and other medical needs. The Company develops therapies that make it possible to regain normalcy for patients suffering from disease. It has three drug candidates in Phase II clinical trials during the year ended December 31, 2008, and six or more other drug candidates in pre-clinical development. The Company's clinical-stage pipeline products include Archexin, an anti-cancer Akt inhibitor; Serdaxin, an antidepressant and CNS Disorders drug, and Zoraxel, an erectile dysfunction (ED) and sexual dysfunction drug.

Message Board Search for RNN: http://www.boardcentral.com/boards/RNN

In the report, the analyst notes:

"RNN recently offered additional commentary, clarifications and insights on its previous announcement of its phase IIa clinical results of Serdaxin® in the treatment of major depressive disorder (MDD).

"Serdaxin® is a potential CNS neuroprotective agent and antidepressant. RNN is currently investigating Serdaxin as a treatment for depression in phase II clinical trials. Serdaxin appears to exhibit therapeutic potential and appears to have no serious side effects such as nausea, vomiting, insomnia, weight gain, sexual dysfunction, cognitive deficit or motor impairment that are linked to existing antidepressant drugs. Serdaxin has a well-established human safety profile."